Medicines Development for Global Health’s sale of its Priority Review Voucher

Hogan Lovells advised Medicines Development for Global Health (MDGH) on the sale

The PRV was awarded to MDGH in June 2018 by the U.S. Food & Drug Administration (FDA) following the FDA’s approval of moxidectin (in patients aged 12 and older ), an oral treatment for river blindness (onchocerciasis), a debilitating disease affecting 20 million people, primarily in low-income countries. The Global Health Investment Fund (GHIF) provided $13 million since 2015 to support MDGH’s efforts to complete clinical studies, manufacture moxidectin and conduct the FDA registration process. As a result of the transaction, significant proceeds will go towards additional research on moxidectin as well as its deployment in key underserved markets, where nearly 200 million individuals are at risk for river blindness.

MDGH was the first non-profit company to be awarded a priority review voucher by the FDA, and moxidectin is the first new FDA-approved treatment for river blindness in the last 20 years.

Hogan Lovells advised MDGH with Adam Golden (Picture), Robert Church and Erin Howell.

Involved fees earner: Robert Church – Hogan Lovells; Adam Golden – Hogan Lovells; Erin Howell – Hogan Lovells;

Law Firms: Hogan Lovells;

Clients: Medicines Development for Global Health;

Author: Ambrogio Visconti